Neurodegenerative Pentara specializes in statistical consulting for neurodegenerative diseases, presenting a targeted opportunity to upsell data management, trial design optimization, and advanced analytics services to pharma and biotech firms focusing on CNS conditions.

AI-Driven Recent collaboration with NetraMark to launch an AI-driven anomaly detection tool signals openness to innovative tech partnerships; leverage this to propose integrated AI-assisted data monitoring, quality control, and real-time trial analytics.

Mid-Sized Advantage With 51-200 employees and revenue in the $25M–$50M range, Pentara sits between boutique and large CROs, making them a prime target for mid-market clinical trial programs, fast onboarding, and flexible pricing for exploratory or Phase I–II studies.

Full Lifecycle Capabilities spanning data management, study design, and statistical analysis from initiation to results presentation suggest opportunities to offer end-to-end services, including data standards onboarding and regulatory-ready reporting packages.

Growth & Markets Location in Utah with a focused niche in neurodegenerative research positions Pentara for regional expansion partnerships and collaborations with larger CROs seeking specialized statistical expertise to strengthen CNS trial portfolios.